Amendments to the Claims

1. (Original) A compound of Formula I:



(I)

wherein:

$D^1$ is a $C_1$-$C_3$ alkane-diyl;

$D^2$ is CH or nitrogen;

$D^4$ is oxygen or sulfur;

$R^1$ is phenyl,

which phenyl is optionally substituted with one to three substitutents independently selected from the group consisting of halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy;

$R^2$ is selected from the group consisting of hydroxy, $C_1$-$C_4$ alkyl, optionally substituted phenyl, naphthyl, $C_3$-$C_{10}$ cycloalkyl, pyridyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl,

which $C_1$-$C_4$ alkyl is optionally substituted with hydroxy, $C_1$-$C_2$ alkoxy, optionally substituted phenyl, pyridyl, $-NR^6R^7$, or naphthyl;

which pyridyl is further optionally substituted with one to two halo, $C_1$-$C_3$ alkyl;

$R^3$ is $C_1$-$C_4$ alkyl, optionally substituted phenyl, $-C(O)-R^4$, or $-S(O)_2-R^4$,

which $C_1$-$C_4$ alkyl is further optionally substituted with $R^4$;

$R^4$ is optionally substituted phenyl;

or $R^2$ and $R^3$, together with the nitrogen to which they are attached, form a 4-11 membered heterocyclic ring,

which heterocyclic ring is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, $C_3$-$C_6$ cycloalkyl, pyridyl, halo, hydroxy, oxo, and $C_1$-$C_4$ alkyl;

wherein the $C_1$-$C_4$ alkyl is further optionally substituted with one to two substituents selected from the group consisting of $C_1$-$C_3$ alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl;

$R^6$ and $R^7$ are each independently hydrogen, $C_1$-$C_4$ alkyl, $-S(O)_2-CH_3$, or $C_1$-$C_4$ alkoxycarbonyl, or $R^6$ and $R^7$, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

$R^5$ is hydrogen, halo, trifluoromethyl, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, $C_3$-$C_6$ cycloalkyl, furyl, pyrazolyl, imidazolyl, $-NR^{13}R^{14}$, pyridyloxy, benzyloxy, phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino,

which phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino group may be optionally substituted on the ring with one to two substituents independently selected from the group consisting of halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, trifluoromethyl, and $-S(O)_q(C_1$-$C_4$ alkyl),

or $R^5$ is a radical selected from the group consisting of:


(IC) , and 

(ID) ;

wherein

W is a bond, $-CHR^{15}-$, -C(O)-, -O-, $-NR^{15}-$, or $-S(O)_q-$;

q is 0, 1, or 2;

$R^{15}$ is selected from the group consisting of hydrogen, hydroxy, $C_1$-$C_4$ alkyl, acetyl, carbamoyl, phenyl, benzyl, and $-S(O)_2CH_3$;

$Z^1$, $Z^2$, and $Z^3$ are each independently CH or nitrogen;

$R^{13}$ and $R^{14}$ are each independently hydrogen, $C_1$-$C_4$ alkyl, $-S(O)_2$-$CH_3$ or $C_3$-$C_6$ cycloalkyl;

wherein the $C_1$-$C_4$ alkyl is optionally substituted with one $C_1$-$C_2$ alkoxy or di($C_1$-$C_2$ alkyl)amino;

or $R^{13}$ and $R^{14}$, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

which 4-7 membered saturated heterocyclic ring is further optionally substituted with one to two $C_1$-$C_2$ alkyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that the following compounds are not claimed: [5-methyl-1-(3-pyrrolidin-1-ylpropyl)-1H-1,2,3-triazol-4-yl]piperazin-1-yl-methanone; {1-[2-(4-nitrophenyl)ethyl]-5-methyl-1H-1,2,3-triazol-4-yl}piperazin-1-yl-methanone; [1-(4-methoxybenzyl)-5-methyl-1H-1,2,3-triazol-4-yl]piperazin-1-yl-methanone; [5-methyl-1-(3-imidazol-1-ylpropyl)-1H-1,2,3-triazol-4-yl]piperazin-1-yl-methanone; (5-methyl-1-benzyl-1H-1,2,3-triazol-4-yl)piperazin-1-yl-methanone; (1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-1,4-diazepan-1-yl-methanone; [1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazol-4-yl]-morpholin-4-yl-methanone; 1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-(2-chloro-benzyl)-amide dihydrochloride; 1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-(2-chloro-benzyl)-amide hydrochloride; 1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-

[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-[1-(2-chloro-phenyl)-ethyl]-amide dihydrochloride; 1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridyl-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-[1-(2-chloro-phenyl)-ethyl]-amide dihydrochloride; {2-[[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-(2-chloro-benzyl)-amino]-ethyl}-carbamic acid tert-butyl ester; {2-[[1-(3,5-bis-trifluoromethyl-benzyl)-5-chloro-1H-[1,2,3]triazole-4-carbonyl]-(2-chloro-benzyl)-amino]-ethyl}-carbamic acid tert-butyl ester; (2-{[1-(3,5-bis-trifluoromethyl-benzyl)-5-chloro-1H-[1,2,3]triazole-4-carbonyl]-[1-(2-chloro-phenyl)-ethyl]-amino}-ethyl)-carbamic acid tert-butyl ester; (2-{[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-[1-(2-chloro-phenyl)-ethyl]-amino}-ethyl)-carbamic acid tert-butyl ester; {2-[[1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-(2-chloro-benzyl)-amino]-ethyl}-carbamic acid tert-butyl ester; and (2-{[1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-[1-(2-chloro-phenyl)-ethyl]-amino}-ethyl)-carbamic acid tert-butyl ester.

2. (Original) The compound of **Claim 1** wherein $D^4$ is oxygen.

3. (Previously Presented) The compound of **Claim 2** wherein $D^2$ is nitrogen.

4. (Previously Presented) The compound of **Claim 3** wherein $D^1$ is methylene.

5. (Previously Presented) The compound of **Claim 4** wherein $R^1$ is 3,5-bis-trifluoromethyl-phenyl.

6. (Previously Presented) The compound of **Claim 5** wherein $R^5$ is phenyl.

7. (Previously Presented) The compound of **Claim 6** wherein $R^2$ is $C_1$-$C_4$ alkyl, which is optionally substituted with optionally substituted phenyl.

8. (Original) The compound of **Claim 7** wherein $R^2$ is 2-chloro-benzyl.

9. (Previously Presented) The compound of **Claim 8** wherein $R^3$ is $C_1$-$C_4$ alkyl, which $C_1$-$C_4$ alkyl is optionally substituted with $R^4$.

10. (Original) The compound of **Claim 9** wherein $R^3$ is methyl.

11. (Previously Presented) The compound of **Claim 6** wherein $R^2$ and $R^3$, together with the nitrogen to which they are attached, form a 4-11 membered heterocyclic ring, which heterocyclic ring is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, $C_3$-$C_6$ cycloalkyl, pyridyl, halo, hydroxy, oxo, and $C_1$-$C_4$ alkyl,

wherein the $C_1$-$C_4$ alkyl is further optionally substituted with one to two substituents selected from the group consisting of $C_1$-$C_3$ alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl.

12. (Original) The compound of **Claim 11** wherein $R^2$ and $R^3$, together with the nitrogen to which they are attached, form pyrrolidin-1-yl, which pyrrolidin-1-yl is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, $C_3$-$C_6$ cycloalkyl, pyridyl, halo, hydroxy, oxo, and $C_1$-$C_4$ alkyl,

wherein the $C_1$-$C_4$ alkyl is further optionally substituted with one to two substituents selected from the group consisting of $C_1$-$C_3$ alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl.

13. (Original) The compound of **Claim 12** wherein $R^2$ and $R^3$, together with the nitrogen to which they are attached, form 2-(2-chloro-phenyl)-pyrrolidin-1-yl.

14. (Original) The compound of **Claim 1** wherein the compound is 1-(3,5-Bis-trifluoromethyl-benzyl)-5-phenyl-1H-[1,2,3]triazole-4-carboxylic acid (2-chloro-benzyl)-methyl-amide.

15. (Original) The compound of **Claim 1** wherein the compound is [1-(3,5-Bis-trifluoromethyl-benzyl)-5-phenyl-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)-pyrrolidin-1-yl]-methanone.

16. (Original) A pharmaceutical composition comprising a compound of **Claim 1**, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

17. (Withdrawn) A method for treating a condition associated with an excess of tachykinins, comprising: administering to a patient in need thereof an effective amount of a compound of Formula (I):



(I)

wherein:

$D^1$ is a $C_1$-$C_3$ alkane-diyl;

$D^2$ is CH or nitrogen;

$D^4$ is oxygen or sulfur;

$R^1$ is phenyl,

which phenyl is optionally substituted with one to three substitutents independently selected from the group consisting of halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy;

$R^2$ is selected from the group consisting of hydroxy, $C_1$-$C_4$ alkyl, optionally substituted phenyl, naphthyl, $C_3$-$C_{10}$ cycloalkyl, pyridyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl,

which $C_1$-$C_4$ alkyl is optionally substituted with hydroxy, $C_1$-$C_2$ alkoxy, optionally substituted phenyl, pyridyl, $-NR^6R^7$, or naphthyl;

which pyridyl is further optionally substituted with one to two halo, $C_1$-$C_3$ alkyl;

$R^3$ is $C_1$-$C_4$ alkyl, optionally substituted phenyl, $-C(O)-R^4$, or $-S(O)_2-R^4$,

which $C_1$-$C_4$ alkyl is further optionally substituted with $R^4$;

$R^4$ is optionally substituted phenyl;

or $R^2$ and $R^3$, together with the nitrogen to which they are attached, form a 4-11 membered heterocyclic ring,

which heterocyclic ring is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, $C_3$-$C_6$ cycloalkyl, pyridyl, halo, hydroxy, oxo, and $C_1$-$C_4$ alkyl;

wherein the $C_1$-$C_4$ alkyl is further optionally substituted with one to two substituents selected from the group consisting of $C_1$-$C_3$ alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl;

$R^6$ and $R^7$ are each independently hydrogen, $C_1$-$C_4$ alkyl, $-S(O)_2-CH_3$, or $C_1$-$C_4$ alkoxycarbonyl, or $R^6$ and $R^7$, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

$R^5$ is hydrogen, halo, trifluoromethyl, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, $C_3$-$C_6$ cycloalkyl, furyl, pyrazolyl, imidazolyl, $-NR^{13}R^{14}$, pyridyloxy, benzyloxy, phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino,

which phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino group may be optionally substituted on the ring with one to two substituents independently selected from the group consisting of halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, trifluoromethyl, and $-S(O)_q(C_1$-$C_4$ alkyl),

or $R^5$ is a radical selected from the group consisting of:


(IC) , and 

(ID) ;

wherein

W is a bond, $-CHR^{15}-$, $-C(O)-$, $-O-$, $-NR^{15}-$, or $-S(O)_q-$;

q is 0, 1, or 2;

$R^{15}$ is selected from the group consisting of hydrogen, hydroxy, $C_1$-$C_4$ alkyl, acetyl, carbamoyl, phenyl, benzyl, and $-S(O)_2CH_3$;

$Z^1$, $Z^2$, and $Z^3$ are each independently CH or nitrogen;

$R^{13}$ and $R^{14}$ are each independently hydrogen, $C_1$-$C_4$ alkyl, $-S(O)_2$-$CH_3$ or $C_3$-$C_6$ cycloalkyl;

wherein the $C_1$-$C_4$ alkyl is optionally substituted with one $C_1$-$C_2$ alkoxy or di($C_1$-$C_2$ alkyl)amino;

or $R^{13}$ and $R^{14}$, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

which 4-7 membered saturated heterocyclic ring is further optionally substituted with one to two $C_1$-$C_2$ alkyl;

or a pharmaceutically acceptable salt thereof.

18. (Withdrawn) The method of **Claim 17** wherein the condition associated with an excess of tachykinins is selected from the group consisting of depression, anxiety, irritable bowel syndrome, and emesis.

19.- 20. (Cancelled)

21. (Original) A compound selected from the group consisting of: [1-(3,5-Bis-trifluoromethyl-benzyl)-5-(1-oxy-pyridin-4-yl)-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)pyrrolidin-1-yl]-methanone, [1-(3,5-Bis-trifluoromethyl-benzyl)-5-(1-oxy-pyridin-3-yl)-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)-pyrrolidin-1-yl]-methanone, and (*R*)-[1-(3,5-Bis-trifluoromethyl-benzyl)-5-(3,6-dihydro-2H-pyridin-1-yl)-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)-pyrrolidin-1-yl]-methanone.